Organisation paid for research Program year 2020 Source: CMS Open Payments

Academic Dermatology Associates

Neither a doctor nor a teaching hospital

Research payments

$57,339

7 payments

Through program year 2020, Academic Dermatology Associates is reported as receiving $57,339 in research payments, across 7 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$5,502	1
2019	Research	$51,837	6

Breakdown

Who paid Research payments · program years 2019–2020

Perrigo Company plc $31,950 1 payment
Ucb SA $21,047 5 payments
Eli Lilly and Company $4,343 1 payment

Studies the money was for Research payments · program years 2019–2020

Bioequivalence study between Perrigo's product and Epiduo Forte Gel $31,950 1 payment
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed By A Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis $13,528 1 payment
A PHASE 3, MULTICENTER, randomized, double-blind, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED, parallel-group study to EVALUATE the EFFICACY AND safety of bimekizumab in adult subjects with moderate to $5,502 1 payment
A 12 Week Multicenter Randomized Double Blind Placebo-Controlled Study Comparing the Efficacy and Safety of Ly2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With A Long Term Extension Period $4,343 1 payment
A Phase 3 Multicenter, randomized, double-blind, placebo - and active comparator-controlled, parallel group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis $1,984 2 payments
A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. $33 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.